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Abstract
Objective—To assess associations and genotype × treatment interactions for melanocortin 4
receptor (MC4R) locus variants and obesity-related traits.
Design and Methods—Diabetes Prevention Program (DPP) participants (N=3,819, of whom
3,356 were genotyped for baseline and 3,234 for longitudinal analyses) were randomized into
intensive lifestyle modification (diet, exercise, weight loss), metformin or placebo control.
Adiposity was assessed in a subgroup (n=909) using computed tomography. All analyses were
adjusted for age, sex, ethnicity and treatment.
Results—The rs1943218 minor allele was nominally associated with short-term (6 month;
P=0.032) and long-term (2 year; P=0.038) weight change. Eight SNPs modified response to
treatment on short-term (rs17066856, rs9966412, rs17066859, rs8091237, rs17066866,
rs7240064) or long-term (rs12970134, rs17066866) reduction in body weight, or diabetes
incidence (rs17066829) (all Pinteraction <0.05).
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tConclusion—This is the first study to comprehensively assess the role of MC4R variants and
weight regulation in a weight loss intervention trial. One MC4R variant was directly associated
with obesity-related traits or diabetes; numerous other variants appear to influence body weight
and diabetes risk by modifying the protective effects of the DPP interventions.
Keywords
MC4R; Randomized Controlled Trial; Lifestyle; Metformin; Gene-Environment Interaction;
Genetic; Obesity; Diabetes Prevention Program; Adiposity
INTRODUCTION
Obesity is a highly heritable(1), complex trait presumed to originate from interactions
between multiple genetic and environment risk factors. Several well-defined genetic causes
of monogenic obesity are known(2), as are multiple low-penetrance obesogenic variants that
are prevalent in the general population(3).
One of the loci implicated in both monogenic and common forms of obesity is the
melanocortin 4 receptor (encoded by MC4R). Mutations in MC4R are the most frequent
known genetic causes of congenital obesity(4) and a variant mapping to a region upstream
of MC4R is strongly associated with variations in BMI and adiposity in multiple
populations(5). MC4R variants have also been associated with energy balance behaviors(6,
7), blood pressure(8), dyslipidemia(9), stature(4), and type 2 diabetes(10).
Two important risk factors for obesity are physical inactivity and excessive caloric intake.
Thus, studies focusing on the interactions between obesity-predisposing genes and therapies
that influence body weight may help elucidate the molecular mechanisms underlying obesity
and its consequences, such as cardiovascular disease, certain cancers, osteoarthritis, and type
2 diabetes. In this regard, lifestyle interventions focused on diet, exercise, and
pharmacologic interventions that influence weight loss (e.g., metformin) are relevant.
The purpose of this study was to extend earlier studies that center on MC4R variants and
BMI by examining whether MC4R variation per se is associated with obesity-related traits
over time or type 2 diabetes incidence. We tagged the entire MC4R region and examined
whether associations with obesity-related traits are mediated by dietary preference or
physical activity or modified by metformin treatment or lifestyle intervention. All analyses
were performed within the Diabetes Prevention Program (DPP), a randomized clinical trial
of intensive lifestyle modification, metformin or troglitazone therapy, or placebo
intervention.
METHODS and PROCEDURES
The Diabetes Prevention Program (DPP)
The DPP was a multi-center randomized clinical trial. The study design and details of the
preventive interventions have been described in detail previously(11-13). Briefly, non-
diabetic, overweight persons (n=3,234) with raised fasting and post-challenge glucoses were
randomized to placebo, metformin (850 mg twice daily), troglitazone (400 mg daily), or a
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tprogram of intensive lifestyle modification (aimed at ~7% weight loss and ~150 minutes of
physical activity per week). A further 585 participants were randomized to receive
troglitazone treatment; owing to liver toxicity, this aspect of the DPP trial was terminated
early and only the baseline results were used in these analyses(11). Thus, a total of 3,819
participants were included in the baseline analyses reported here, whereas 3,234 are
included in the prospective analyses. The principal endpoint in the DPP was the
development of diabetes by confirmed oral glucose tolerance testing (OGTT). Other
phenotypes, such as changes in weight, waist circumference, abdominal fat area, lipids,
insulin and glucose, were also collected. The primary focus of this report is on the obesity-
related traits; the secondary focus is on diabetes incidence. Each of the 27 DPP centers
obtained approval from their respective institutional review boards prior to initiation of the
study protocol.
Consent for genetic analyses was obtained in 87.9% (n=3,356/3,819) of participants who
were originally assigned to a treatment arm in the DPP. Of the participants studied in this
report, by self-report 56.1% were white, 20.4% African American, 16.7% Hispanic, 4.4%
Asian American and 2.5% American Indian. Concordant with the entire DPP, the
participants’ mean age at enrollment was 51 (SD=11) years and mean body mass index
(BMI) was 34 (SD=7) kg/m2; (see Table 1).
Quantification of energy intake, physical activity, and body composition
In-person interviews were conducted to obtain data on calorie intake, percent of calories
from fat and protein, absolute intake of fat and protein and food preference behaviors at
baseline and 1 year later using the semi-quantitative DPP food frequency questionnaire
(FFQ)(14). To evaluate food preference behaviors, we assessed the frequency of
consumption of snacks, sweets and desserts, vegetables and fruits, expressed as servings per
day. Occupational and leisure-time physical activity (LTPA) was assessed using the
validated Modifiable Activity Questionnaire (MAQ) at baseline and annually thereafter(15).
Weight and BMI were measured in all participants.
Computed tomography (CT) was performed at baseline in 909 randomly selected subjects
DPP participants, among whom 718 underwent a repeated measure at 12-months post-
randomization to quantify subcutaneous and visceral fat areas (at the level of the lumbar 2-3
disc space)(16) and gave consent for genetic analyses. Among the participants with both
baseline and one-year CT measurements, 241 were from the intensive lifestyle group, 246
from the metformin group and 231 from the placebo group.
Genotyping
SNPs were selected through multimarker tagging of the MC4R locus (as previously
described(17)). Genotyping was performed by allele-specific primer extension of multiplex
amplified products and detection with matrix-assisted laser desorption ionization-time of
flight mass spectroscopy on a Sequenom iPLEX platform. The genotyping success rates for
the SNPs studied here were >99%. All 20 SNPs were in Hardy-Weinberg equilibrium in all
five ethnic groups (P>0.05). For each SNP, genomic location, alleles and their frequencies
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tare reported in Online Supplementary Table 1. Online Supplementary Figures 1a-e show the
LD plots for these variants.
Statistical analysis
Analyses were performed using the SAS software (SAS Institute, Cary, NC). Weight loss
and abdominal fat area follow-up data were normally distributed and linear regressions were
employed for these outcomes. SNP associations with diabetes incidence were assessed with
Cox proportional hazards models. Potential mediating effects of leisure time physical
activity (LTPA) and energy intake were tested by comparing the SNP regression coefficients
with and without adjustment for the potential mediators(17). All models were adjusted for
genotype, intervention, baseline value of the dependent variable, age at randomization, sex,
and self-reported ethnicity. Further adjustment for study center made no material difference
to the results (data not shown) and is thus not included in the current models. To determine
whether it was appropriate to combine data from different treatment and ethnicity groups,
we tested genotype × treatment and genotype × ethnicity interactions. If these tests were
statistically significant (P<0.05), we stratified by group; otherwise data were pooled and
adjusted for treatment and/or ethnicity. For all variants, we analyzed additive genetic
models. Two-sided P-values without multiplicity adjustment are reported.
MC4R is a strong candidate gene for obesity-related traits(4); thus, the prior probability that
variants at this locus are associated with obesity traits is likely to be above the null.
Moreover, although the DPP is the largest randomized controlled trial of intensive lifestyle
modification, it is modestly powered for most of the tests performed here (see:(18)) for
description of the statistical power characteristics of the DPP). Thus, correcting for multiple
testing is likely to increase type 2 error (false-negative) rates. Nonetheless, we are conscious
that many readers will be keen to compare the nominal test statistics with those corrected for
multiple testing. After considering the linkage disequilibrium between the 20 SNPs, we
determined that there are 17.46 independent SNP tests(19). Therefore, instead of the
Bonferroni cutoff of 0.05, a cutoff of 0.05/17.46=0.003 is used to determine a conservative
estimate of statistical significance for the results reported in this paper.
Exploratory analyses were performed to determine whether any of the statistically
significant genetic effects detected in the main analyses were likely to be mediated by
specific lifestyle factors. The following factors were considered potential intermediate
factors (mediators) of the observed genetic effects: leisure time physical activity in MET-hrs
per week (metabolic equivalents), total caloric intake (kcal/day), percent of calories from fat,
percent of calories from protein, fat intake (g/day), protein intake (g/day), snacking (number
of snacks/day), sweet and dessert (servings/day), vegetable consumption (servings/day) and
fruit consumption (servings/day).
While testing each candidate mediator, two models were fit, one with the candidate mediator
as a covariate and the other without. From each pair of models, the difference in the two
SNP regression coefficients and the standard errors of these differences were calculated(18).
In these analyses, a statistically significant non-zero difference represents a discrepancy
between the marginal SNP effect estimate and the SNP effect estimate that is conditional on
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tthe putative mediator, thus validating the intermediate function of the mediator from
genotype to the outcome.
RESULTS
Participant characteristics
Participant characteristics for the DPP cohort used for genetic analyses are reported
elsewhere(17). Table 1 reports anthropometric traits, energy intake, and physical activity at
baseline, as well as the weight loss outcomes.
Table 2 shows results from the analysis focused on the entire MC4R region; the table shows
regression coefficients (representing the average difference in the dependent variable for
each additional copy of the minor allele) and P values for all 20 MC4R SNPs and baseline
weight and BMI in DPP participants. After adjustment for age, sex, and self-reported
ethnicity, no SNP was statistically associated with baseline weight or BMI.
SNP associations with change in weight or adiposity
Tables 3 and 4 list the overall and treatment specific genetic effects for the three major
outcomes: short-term (baseline to 6 months) and long-term (baseline to 2 years) weight
change, and diabetes incidence. The major ‘C’ allele at SNP rs1943218 was associated with
less short-term (P=0.032) and long-term (P=0.038) weight loss. Seven SNPs modified
response to treatment on short-term (rs17066856, rs9966412, rs17066859, rs8091237,
rs17066866, rs7240064) or long-term (rs12970134, rs17066866) reduction in body weight.
Among them, nominally statistically significant associations with weight change for
rs7240064 in the placebo arm and rs9966412 and rs17066859 in the metformin arm were
observed, with each SNP’s minor allele being associated with less short-term weight loss.
The minor allele of rs17066866 was associated with less short-term (P=0.006) and less long-
term (P=0.004) weight loss in the lifestyle intervention group, the latter of which
approached the multiple-testing corrected significance threshold (P=0.003).
Associations with diabetes incidence
Table 4 shows the SNP association results for type 2 diabetes incidence. SNP rs17066829
showed nominal evidence of interaction with treatment for diabetes risk (Pinteraction <0.05);
for example, each copy of the minor allele at SNP rs17066829 corresponded to a HR of 0.80
(95% CI: 0.64-1.00) in the lifestyle group, which contrasted the effect observed in the
placebo group (HR=1.09; 95% CI: 0.92-1.29).
Examining dietary factors and physical activity as putative mediators of genetic effects on
obesity traits
Potential mediators were examined for all SNP associations and interactions that were of at
least nominal statistical significance (as shown in Tables 3 and 4). No significant differences
between the SNP effects before or after the adjustment of each potential mediator were
detected.
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tDISCUSSION
MC4R is a strong candidate gene for diabetes and obesity-related traits. The rs17782313
SNP, which is upstream of the MC4R locus, has for example been reliably associated with
common obesity in a GWAS meta-analysis(5) and also in the DPP(17), but the MC4R region
in general has been of continued interest in obesity research for many years(3,5,10,21),
largely because of its established role in monogenic obesity(4). Hence, we examined
common variation across MC4R to seek a more detailed understanding of the role the gene
plays in obesity and diabetes, and to determine whether the apparent obesogenic effect of
variation at this locus is modified by weight loss interventions in the DPP.
In analyses adjusted for multiple statistical comparisons, we found nominal evidence of
association between the rs1943218 variant and short- (baseline to 6 months) and long-
(baseline to two years) term weight loss. Interactions between metformin treatment and the
rs9966412 and rs17066859 variants on short-term weight loss were also found. Moreover,
we observed a nominally significant statistical interaction between the rs17066829 SNP and
treatment on diabetes incidence, which is of potential interest, as a recent study also showed
that this variant was associated with BMI(22).
MC4R is centrally expressed and binds the α, β and γ isoforms of melanocortin-stimulating
hormone (MSH) and adrenocoticotropic hormone (ACTH) with varying affinity, while
Agouti and Agouti-related protein (AgRP) are endogenous MC4R antagonists(23). Mc4r
knockout mice are hyperphagic and are prone to maturity-onset obesity(24). Although
restricting food availability reduces body weight in female Mc4r -/- mice, these animals
remain susceptible to obesity(25), indicating that MC4R ablation also influences energy
expenditure; direct evidence for this comes from observations that Mc4r null mice have
lower resting oxidative energy metabolism(25) and dark-phase locomotor activity(25,26)
compared with wild type animals. People heterozygous for specific MC4R mutations are
MC4R deficient and are often hyperphagic, heavier and taller, with more fat and lean mass,
and have higher bone mineral content than people who do not carry these mutations(27).
Genome-wide scans of White Europeans have identified two independent signals for BMI at
the MC4R locus, which are also associated with adipose mass and type 2 diabetes(10). One
of the most thorough investigations of the MC4R locus in humans to date was undertaken by
Thearle et al in a study of 6,760 persons of predominantly Pima Indian ancestry(28). The
authors sequenced the MC4R exon to discover six low frequency mutations (~2.4%), which
were subsequently functionally interrogated in vitro. These mutations conveyed an effect on
weight gain but this was only evident in childhood, and the effect on type 2 diabetes that the
authors observed was mediated by adult BMI.
MC4R is a strong candidate gene for obesity-related traits; thus, the prior probability that
variants at this locus are associated with obesity traits is likely to be above the null, in which
case the nominal P-values we report here may be somewhat conservative estimates of the
underlying probability that an association exists. Moreover, although the DPP is the largest
randomized controlled trial of intensive lifestyle modification, it is modestly powered for
most of the tests performed here(17) for description of the statistical power characteristics of
the DPP). Thus, correcting for multiple testing is likely to increase type 2 error (false-
Pan et al. Page 6
Obesity (Silver Spring). Author manuscript; available in PMC 2014 May 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tnegative) rates. Nonetheless, we are conscious that many readers will be keen to compare
the nominal test statistics with those corrected for multiple testing, which is why the
multiple-test corrected significance threshold is given above.
Assessing epidemiological observations in an experimental setting is important step in the
process of translating such observations into preventive action. Nevertheless, it is important
to bear in mind that DPP participants were recruited on the basis of being overweight or
obese and having impaired fasting and post-challenge glucose. Thus, the findings from this
study may not generalize to other population subgroups. We were also unable to identify
behavioral factors that might mediate the effects of MC4R on obesity-related traits, which
would have aided the interpretation of the results described above. Our study was also
limited by the absence of information on lifestyle behaviors after 12 months of intervention,
which may have hampered the detection of mediators.
In summary, we have conducted the first comprehensive analysis of common genomic
variation at the MC4R locus in relation to changes in body composition and incidence of
type 2 diabetes within a randomized controlled trial of weight loss interventions. Our
findings, that several MC4R variants are nominally related to these traits, in some instances
by modifying the effects of weight loss interventions on diabetes incidence and adipose
accumulation, adds novel information on the role of the MC4R locus in the development of
obesity and type 2 diabetes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tWhat is already known about this subject
• MC4R encodes one of five melanocortin receptors that control energy balance,
adipose deposition, and other metabolic traits
• MC4R mutations are the most frequent known cause of human monogenic
obesity
• Common variants in MC4R are associated with common obesity and type 2
diabetes
What this study adds
• This study provides the first a comprehensive assessment of MC4R variation in
relation to dynamic body weight phenotypes in a randomized controlled trial of
weight loss interventions
• Several MC4R variants appear to modify the effects of the DPP weight loss
interventions on reductions in body weight and diabetes incidence
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